Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Celecoxib
Drug ID BADD_D00410
Description Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124]
Indications and Usage For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
Marketing Status Prescription
ATC Code L01XX33; M01AH01
DrugBank ID DB00482
KEGG ID D00567
MeSH ID D000068579
PubChem ID 2662
TTD Drug ID D03RTS
NDC Product Code 70247-006; 42806-720; 43063-967; 72567-001; 16714-731; 59385-055; 67296-1600; 51079-199; 65162-819; 50436-0144; 46708-268; 68788-7735; 80425-0167; 65862-793; 13668-307; 69097-422; 80425-0096; 12598-9531; 69097-423; 12598-9516; 55111-898; 67296-1399; 71335-0868; 60429-460; 71610-283; 57582-032; 61919-360; 29300-373; 68180-398; 0591-3984; 70934-220; 0591-3983; 55289-451; 42571-142; 59762-1518; 51655-253; 68180-399; 62332-140; 60687-436; 57582-213; 68788-7286; 64552-4032; 53104-7533; 42806-722; 76420-009; 71209-056; 70518-1346; 65977-0052; 72189-123; 70934-213; 62704-0046; 59746-563; 77771-157; 0378-7150; 0025-1515; 71205-027; 42571-143; 70518-2748; 80425-0040; 75834-236; 65862-908; 71209-054; 63187-301; 42571-144; 63629-8156; 51927-5063; 55700-613; 13668-441; 53002-1338; 0025-1520; 50090-5178; 69367-302; 60687-447; 75834-237; 55154-7646; 50090-3183; 59762-1515; 0093-7165; 80425-0142; 43063-669; 42806-721; 62332-143; 55154-7645; 0591-3985; 68788-7264; 60505-3847; 60505-3849; 0378-7160; 55700-607; 70518-3204; 60505-3848; 71335-0936; 59762-1516; 69097-420; 0093-7170; 45865-970; 63187-633; 70934-469; 61919-837; 51079-215; 69117-0020; 65862-909; 0615-8338; 50228-156; 75834-239; 68981-025; 68180-396; 68071-4476; 69680-135; 69367-301; 65162-820; 0904-6503; 0378-7170; 52048-1995; 29300-157; 16714-734; 50268-168; 77771-156; 33342-158; 77777-115; 50228-159; 0378-7165; 70247-009; 70247-007; 69117-0021; 50090-5638; 42571-145; 69117-0022; 0093-7166; 70934-026; 51552-1461; 80425-0038; 60760-823; 43063-825; 57582-212; 72969-008; 71209-055; 53002-2338; 13668-310; 42708-016; 71205-020; 80425-0039; 67296-1608; 59746-561; 71610-584; 77771-159; 47621-024; 63187-643; 71335-0292; 0025-1530; 65162-818; 77771-158; 65862-910; 80425-0037; 67296-1345; 75834-238; 63187-562; 71335-2019; 71205-439; 71205-055; 65427-002; 60429-462; 13668-442; 62332-141; 62512-0018; 29300-158; 33342-156; 0025-1525; 68071-4392; 58159-067; 46708-267; 72241-025; 60429-461; 46708-270; 68071-4642; 70518-3292; 59762-1517; 65691-0048; 55289-475; 0904-6502; 50228-157; 57582-214; 61919-043; 69097-421; 71335-1804; 72241-023; 62332-142; 43353-257; 60760-824; 63187-079; 29300-374; 16714-733; 0591-3982; 50228-158; 43744-071; 50090-4789; 71209-057; 46708-838; 33342-155; 16714-732; 59746-564; 49706-1880; 63629-3021; 50268-169; 45865-943; 65162-817; 66651-919; 69117-0023; 72761-022; 71335-1066; 68180-395; 68724-1004; 68071-2626; 70518-2922; 65015-882; 57582-211; 33342-157; 72241-022; 45865-840; 46708-269; 65862-907; 42806-723; 59746-562; 60760-209; 0093-7306; 54245-3392; 70247-008; 61919-682; 60429-459; 72241-024
Synonyms Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635
Chemical Information
Molecular Formula C17H14F3N3O2S
CAS Registry Number 169590-42-5
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.000919%Not Available
Crying12.02.11.001; 08.01.03.005; 19.04.02.002; 17.02.05.0130.000574%Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000345%
Cyst16.02.02.002; 08.03.05.001--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.001--Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000060%Not Available
Depressed mood19.15.02.001--Not Available
Depression19.15.01.0010.004250%
Dermatitis23.03.04.002--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.0020.001263%
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000689%
Diabetes mellitus14.06.01.001; 05.06.01.0010.001034%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.000689%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000804%Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.0010.000345%Not Available
Diverticulum07.10.01.0010.000230%Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Drug eruption10.01.01.005; 23.03.05.001; 08.01.06.0150.002182%Not Available
Drug hypersensitivity10.01.01.0010.106362%Not Available
Drug interaction08.06.03.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 24 Pages